Table 2.

Clinical characteristics of patients who suffered a fragility fracture versus those who did not.

Variable	Fragility fracture (n=6)	No fracture (n=40)	p
Mean daily prednisolone dose, mg (SD)	14.85 (7.1)	14.32 (6.2)	0.84
High-dose prednisolone (>7.5mg) for ≥ 3 months, No. (%)	4 (66.7%)	34 (85.0%)	0.28
Antiresorptive therapy, No. (%)	0 (0.0%)	17 (42.5%)
<<<Alendronate, 70 mg/week		13 (32.5%)	0.04
<<<Risedronate, 35 mg/week		3 (7.5%)
<<<Denosumab, 60 mg 6mthly		1 (2.5%)
Calcium/vitamin D supplementation*, No (%)	3 (50.0%)	34 (85.0%)	0.04
Baseline BMD (NOF)
<<<Normal (T score >-1.0)	5 (83.3%)	12 (30%)	0.03
<<<Abnormal (T score<-1.0)	1 (16.7%)	28 (70%)